Info

Poniard Pharmaceuticals Inc. (Poniard) is a biopharmaceutical company focused on the development and commercialization of cancer therapy products. Its lead product candidate is picoplatin, a new generation platinum-based cancer therapy with an improved safety profile. An intravenous chemotherapeutic agent, picoplatin is designed to overcome platinum resistance in the treatment of solid tumors. Based on positive interim median overall survival data from the ongoing Phase II study, the Company initiated a Phase III SPEAR (Study of Picoplatin Efficacy After Relapse) trial of picoplatin in small cell lung cancer. The Company is also conducting separate Phase I/II studies of picoplatin in the treatment of patients with metastatic colorectal cancer and hormone-refractory prostate cancer. NeoRx Manufacturing Group, Inc. is a wholly owned subsidiary of the Company.(Source: 10-K)